KR970705990A - 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders) - Google Patents

피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)

Info

Publication number
KR970705990A
KR970705990A KR1019970701625A KR19970701625A KR970705990A KR 970705990 A KR970705990 A KR 970705990A KR 1019970701625 A KR1019970701625 A KR 1019970701625A KR 19970701625 A KR19970701625 A KR 19970701625A KR 970705990 A KR970705990 A KR 970705990A
Authority
KR
South Korea
Prior art keywords
inhibitor
pharmaceutical composition
cholesterol synthesis
lovastatin
skin
Prior art date
Application number
KR1019970701625A
Other languages
English (en)
Inventor
나프탈리 사비온
사라 브레너
Original Assignee
하나넬 크바틴스키, 라미 핀클러
라모트 유니버시티 오소리티 퍼 어플라이드 리써치 앤드 인더스트리얼 디벨로프먼트 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하나넬 크바틴스키, 라미 핀클러, 라모트 유니버시티 오소리티 퍼 어플라이드 리써치 앤드 인더스트리얼 디벨로프먼트 엘티디. filed Critical 하나넬 크바틴스키, 라미 핀클러
Publication of KR970705990A publication Critical patent/KR970705990A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

콜레스테롤 합성 억제제가 피부 질환의 치료, 완화 또는 예방에 사용된다.

Description

피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 유효성분으로서 유효량의 콜레스테롤 합성 억제제 및 담체를 포함하는 국소 피부 투여용 조성물.
  2. 제1항에 있어서, 제약 조성물인 조성물.
  3. 제2항에 있어서, 콜레스테롤 합성 억제제가 3-히드록시-3-메틸글루타릴 조효소 A(MHG-CoA) 환원 효소의 억제제인 제약 조성물.
  4. 제3항에 있어서, 억제제가 로바스타틴인 제약 조성물.
  5. 제4항에 있어서, 로바스타틴의 농도가 약 0.2 내지 10%인 제약 조성물.
  6. 제5항에 있어서, 로바스타틴의 농도가 약 2%인 제약 조성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 심상성 좌창, 건선, 두피 비듬 및 사보레아(saborea)로 이루어지는 군으로부터 선택된 피부 질환 치료용 제약 조성물.
  8. 제7항에 있어서, 항균제, 박리제 또는 각종의 레티노에이드로 이루어지는 군으로부터 선택된 여드름 방지제를 포함하는 여드름 치료용 제약 조성물.
  9. 피부 질환의 치료, 완화 또는 예방용의 국소용 제약 조성물 제조를 위한 콜레스테롤 합성 억제제의 용도.
  10. 제9항에 있어서, 콜레스테롤 합성 억제제가 3-히드록시-3-메틸글루타릴 조효소 A(HMG-CoA) 환원 효소의 억제제인 용도.
  11. 제10항에 있어서, 억제제가 로바스타틴인 용도.
  12. 제약상 유효량의 콜레스테롤 합성 억제제를 피부에 국소 투여하는 것을 포함하는 피부질환의 치료, 완화 또는 예방 방법.
  13. 제12항에 있어서, 콜레스테롤 합성 억제제가 3-히드록시-3-메틸글루타릴 조효소 A(HMG-CoA) 환원효소의 억제제인 방법.
  14. 제13항에 있어서, 억제제가 로바스타틴인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701625A 1994-09-13 1995-09-13 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders) KR970705990A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL110943 1994-09-13
IL11094394A IL110943A (en) 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
PCT/US1995/011678 WO1996008248A1 (en) 1994-09-13 1995-09-13 Compositions for the treatment of skin disorders

Publications (1)

Publication Number Publication Date
KR970705990A true KR970705990A (ko) 1997-11-03

Family

ID=11066547

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701625A KR970705990A (ko) 1994-09-13 1995-09-13 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)

Country Status (14)

Country Link
US (1) US6126947A (ko)
EP (1) EP0793489B9 (ko)
JP (1) JP4128616B2 (ko)
KR (1) KR970705990A (ko)
CN (1) CN1106841C (ko)
AT (1) ATE321548T1 (ko)
AU (1) AU694274B2 (ko)
BR (1) BR9509006A (ko)
CA (1) CA2199844C (ko)
DE (1) DE69534908T2 (ko)
IL (1) IL110943A (ko)
MX (1) MXPA97001884A (ko)
RU (1) RU2159611C2 (ko)
WO (1) WO1996008248A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5840752A (en) * 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
FI972040A (fi) * 1997-05-13 1998-11-14 Nokia Telecommunications Oy Menetelmä pakettivälitteiseen tiedonsiirtoon
AU3887399A (en) * 1998-05-05 1999-11-23 Saqib R. Anwel Hair and skin treatment method and composition
FR2801508B1 (fr) * 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6699886B2 (en) * 2001-05-31 2004-03-02 Cellegy Pharmaceuticals, Inc. Store operated calcium influx inhibitors and methods of use
US7060729B2 (en) * 2002-09-05 2006-06-13 Reza Babapour Composition and method for treating skin
AU2003264443A1 (en) * 2002-09-20 2004-04-08 Kowa Co., Ltd. Preparation for external use
US20070042184A1 (en) 2003-08-22 2007-02-22 Danisco A/S Microcapsules
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
KR20060135826A (ko) * 2004-03-31 2006-12-29 코와 가부시키가이샤 외용제
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
GB2459922A (en) * 2008-05-13 2009-11-18 Univ Dundee Treatment for keratinizing dermatological disorders by reduction in keratin expression
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
US20120149775A1 (en) * 2010-11-29 2012-06-14 Shiseido Company, Ltd. Methods for preventing and improving skin elastic property loss
US9273192B1 (en) * 2014-11-06 2016-03-01 George Reck Method of preventing microbial growth on water treatment dispersant
US9925170B2 (en) 2015-10-01 2018-03-27 Kythera Biopharmaceuticals, Inc. Methods of adipolysis and compositions useful therein
CA3041644C (en) 2016-10-24 2020-03-10 Colgate-Palmolive Company Oral care compositions and methods of use
JP2022036341A (ja) * 2018-10-12 2022-03-08 学校法人慶應義塾 慢性皮膚炎の治療のための医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047235A (ko) * 1963-09-09
GB1026927A (en) * 1964-01-20 1966-04-20 Richardson Merrell Inc Triphenylhaloethylenes
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
GB2081580A (en) * 1980-08-07 1982-02-24 Anand Chaman Lal Sapindus trifoliatus extracts
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
DE4303840A1 (de) * 1992-10-22 1994-08-11 Thomae Gmbh Dr K Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
US5466687A (en) * 1992-10-22 1995-11-14 Dr. Karl Thomae Gmbh Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
DE4239151A1 (de) * 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
US5730992A (en) * 1994-09-13 1998-03-24 Ramot University Authority For Applied Research And Industrial Development, Ltd. Compositions for the treatment of skin disorders

Also Published As

Publication number Publication date
EP0793489B1 (en) 2006-03-29
RU2159611C2 (ru) 2000-11-27
IL110943A0 (en) 1994-11-28
BR9509006A (pt) 1998-06-23
JPH10505838A (ja) 1998-06-09
ATE321548T1 (de) 2006-04-15
JP4128616B2 (ja) 2008-07-30
EP0793489B9 (en) 2006-08-30
WO1996008248A1 (en) 1996-03-21
CA2199844C (en) 2007-04-10
DE69534908T2 (de) 2007-01-25
EP0793489A4 (en) 2001-12-19
CA2199844A1 (en) 1996-03-21
EP0793489A1 (en) 1997-09-10
CN1106841C (zh) 2003-04-30
US6126947A (en) 2000-10-03
IL110943A (en) 1997-02-18
AU694274B2 (en) 1998-07-16
AU3717395A (en) 1996-03-29
DE69534908D1 (de) 2006-05-18
CN1158567A (zh) 1997-09-03
MXPA97001884A (es) 2004-04-16

Similar Documents

Publication Publication Date Title
KR970705990A (ko) 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
RU97106064A (ru) Композиции для лечения кожных заболеваний
CA2224528A1 (fr) Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
CA2238465A1 (fr) Composes triaromatiques, compositions les contenant et utilisations
BR0015604A (pt) Método para o tratamento de cicatrizes hipertróficas de modo a reduzir o tamanho e/ou melhorar a aparência das mesmas, composições para tratar condições adversas da pele, e, para reduzir o tamanho e melhorar a aparência de cicatrizes hipertróficas
CA2191129A1 (fr) Medicaments a base de metronidazole ou d'un melange synergetique de metronidazole et de clindamycine
CA2191789A1 (fr) Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
BR0211673A (pt) Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
KR900017590A (ko) 좌창(Acne)치료방법 및 그 약제 조성물
BR0313630A (pt) Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica
BRPI0114344B8 (pt) composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
CA2218766A1 (fr) Composes bicycliques-aromatiques
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
CA2191790A1 (fr) Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
KR960000855A (ko) L-카르니틴염과 이를 함유한 피부질환 치료용 화장품 조성물 및 약제조성물
KR960010002A (ko) L-카르니틴염과 이를 함유한 피부질환 치료용 화장품 조성물 및 약제 조성물
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
TR199700694T1 (xx) D vitamini t�revlerinin dermotolojik kullan�m�.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid